Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback